Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12618001944224
Ethics application status
Approved
Date submitted
28/11/2018
Date registered
30/11/2018
Date last updated
29/04/2024
Date data sharing statement initially provided
30/11/2018
Date results provided
27/03/2023
Type of registration
Prospectively registered

Titles & IDs
Public title
Phase III Trial of Extended Temozolomide in Newly Diagnosed Glioblastoma
Scientific title
To determine if extended post-radiation temozolomide will improve survival outcomes in patients with newly diagnosed glioblastoma
Secondary ID [1] 296725 0
Nil
Universal Trial Number (UTN)
Trial acronym
EX-TEM
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Brain Cancer 310588 0
Glioblastoma 310616 0
Condition category
Condition code
Cancer 309300 309300 0 0
Brain

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
The study will be comparing two standards of care, six versus 12 cycles of post-radiation temozolomide. Temozolomide is a DNA alkylating chemotherapy used in the treatment of glioblastoma.
Arm A: Will receive observation with standard clinical and radiological follow up
Arm B: Will receive an additional six cycles of post-radiation temozolomaide followed by observation with standard clinical and radiological follow up.
The dosage regimen of temozolomide is an oral capsule taken daily for five consecutive days out of every 28 days, at the dose previously tolerated by the patient to a maximum of 200mg/m^2. Adherance will be monitored at four weekly clinical assessments
Intervention code [1] 313033 0
Treatment: Drugs
Comparator / control treatment
Arm A: No treatment. Clinical assessments occur at baseline, and then as per local protocols thereafter. MRI Brain scans are scheduled at baseline, and then as per local protocols thereafter. Haematological/Biochemical assessments will be performed as clinically indicated.
Control group
Active

Outcomes
Primary outcome [1] 308267 0
To determine overall survival impact of an additional six cycles of temozolomide following concurrent chemoradiation and six cycles of post-radiation temozolomide,
Timepoint [1] 308267 0
Time from day one of cycle six plus 28 days to date of death from any cause up until 36 months post randomisation.
Secondary outcome [1] 354477 0
To determine the impact of an additional six cycles of temozolomide on progression-free surivival as assessed by neuro-radiological review using Response Assessment in Neuro-Oncology criteria
Timepoint [1] 354477 0
Time from day one of cycle six plus 28 days to date of death from any cause up until 36 months post randomisation.
Secondary outcome [2] 354478 0
To determine toxicity of an additional six cycles of temozolomide as assessed by recorded adverse event and necessity for temozolomide dose modification in patient medical records.
Timepoint [2] 354478 0
Time from day one of cycle six plus 28 days to date of adverse events up until 36 months post randomisation.

Eligibility
Key inclusion criteria
1. Males or females with newly diagnosed, histologically confirmed glioblastoma
2. Adults, aged 18 years and over
3. Completed radiation plus concurrent temozolomide, followed by six cycles of post-radiation temozolomide
4. No evidence of progressive disease on on-study screening MRI. Residual disease or enhancement is allowed, as long as stability or response according to RANO criteria has been demonstrated compared with prior MRI
5. ECOG 0-2
6. Life expectancy of > 12 weeks
7. Fit for further temozolomide
8. Able to start study treatment within four weeks of day one of cycle six
9. Willing and able to comply with all study requirements, including treatment, timing and/or nature of required assessments
10. Signed, written informed consent.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Progressive disease on on-study screening MRI according to RANO criteria when compared with prior MRI
2. Specific comorbidities or conditions (e.g. psychiatric) or concomitant medications which may interact with the administration of study treatments or procedures
3. Other comorbidities or conditions that may compromise assessment of key outcomes
4. No temozolomide or cranial irradiation in the last five years prior to GBM diagnosis.
5. History of another malignancy within five years prior to registration. Patients with curatively treated carcinoma-in-situ, basal cell carcinoma of the skin, squamous cell carcinoma of the skin or superficial transitional cell carcinoma of the bladder are eligible.
6. Significant infection, including chronic active hepatitis B, hepatitis C or HIV.
7. Concurrent illness,
8. Pregnancy, lactation, or inadequate contraception.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Central randomisation by computer
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Permuted block randomisation
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Safety
Statistical methods / analysis
315 patients will be randomised in a 1:1 ratio to Arm A or Arm B. 248 events will have 80% power at alpha = 0.05 to detect an improvement in overall survival with a hazard ratio of 0.7.
The duration of accrual will be 24 months, and follow up will be 36 months.

Intention-to-treat population of all randomly assigned participants will be used for survival analysis. SAEs and treatment details will be reported for patients receiving at least one dose of study treatment.
Overall survival (OS) will be measured from day one of cycle six plus 28 days and median OS estimated using the nonparametric Kaplan Meier method with 95% CI. Patients will be censored at the time of last follow-up. Hazard ratios for survival will be calculated using Cox proportional hazards and adjusted for study site, type of surgery (resection versus biopsy), ECOG (0-1 versus 2), MGMT methylation (methylated versus unmethylated), duration of radiation (long course versus short course) and residual disease on MRI (present versus absent).
PFS will be analysed in the same manner as OS.
SAEs will be described by the number and percentage of each type.

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
3/12/2018
Actual
13/03/2019
Date of last participant enrolment
Anticipated
1/01/2023
Actual
29/11/2022
Date of last data collection
Anticipated
29/11/2025
Actual
12/03/2024
Sample size
Target
315
Accrual to date
Final
46
Recruitment in Australia
Recruitment state(s)
NSW,QLD,TAS,WA,VIC
Recruitment hospital [1] 12574 0
Royal Hobart Hospital - Hobart
Recruitment hospital [2] 12575 0
Epworth Richmond - Richmond
Recruitment hospital [3] 12576 0
St Vincent's Hospital (Melbourne) Ltd - Fitzroy
Recruitment hospital [4] 12577 0
St Vincents & Mercy Private Hospital - Mercy campus - East Melbourne
Recruitment hospital [5] 13968 0
Bendigo Health Care Group - Bendigo Hospital - Bendigo
Recruitment hospital [6] 13969 0
Princess Alexandra Hospital - Woolloongabba
Recruitment hospital [7] 15096 0
Royal Brisbane & Womens Hospital - Herston
Recruitment hospital [8] 15097 0
The Alfred - Melbourne
Recruitment hospital [9] 15098 0
Southwest Health Care - Warrnambool - Warrnambool
Recruitment hospital [10] 15099 0
Monash Medical Centre - Clayton campus - Clayton
Recruitment hospital [11] 15100 0
Ballarat Health Services (Base Hospital) - Ballarat Central
Recruitment hospital [12] 19386 0
Sir Charles Gairdner Hospital - Nedlands
Recruitment hospital [13] 19387 0
Border Medical Oncology - Albury
Recruitment hospital [14] 19388 0
Goulburn Valley Health - Shepparton campus - Shepparton
Recruitment hospital [15] 19389 0
Westmead Hospital - Westmead
Recruitment postcode(s) [1] 24951 0
7000 - Hobart
Recruitment postcode(s) [2] 24952 0
3121 - Richmond
Recruitment postcode(s) [3] 24953 0
3065 - Fitzroy
Recruitment postcode(s) [4] 24954 0
3002 - East Melbourne
Recruitment postcode(s) [5] 26740 0
3550 - Bendigo
Recruitment postcode(s) [6] 26741 0
4102 - Woolloongabba
Recruitment postcode(s) [7] 28393 0
4029 - Herston
Recruitment postcode(s) [8] 28394 0
3280 - Warrnambool
Recruitment postcode(s) [9] 28395 0
3168 - Clayton
Recruitment postcode(s) [10] 28396 0
3350 - Ballarat Central
Recruitment postcode(s) [11] 33965 0
6009 - Nedlands
Recruitment postcode(s) [12] 33966 0
2640 - Albury
Recruitment postcode(s) [13] 33967 0
3630 - Shepparton
Recruitment postcode(s) [14] 33968 0
2145 - Westmead

Funding & Sponsors
Funding source category [1] 301306 0
Other Collaborative groups
Name [1] 301306 0
The Walter and Eliza Hall Institute of Medical Research
Country [1] 301306 0
Australia
Primary sponsor type
Other Collaborative groups
Name
The Walter and Eliza Hall Institute of Medical Research
Address
Walter and Eliza Hall institute
1G Royal Parade
Parkville VIC 3052
Country
Australia
Secondary sponsor category [1] 300961 0
None
Name [1] 300961 0
Address [1] 300961 0
Country [1] 300961 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 302047 0
Melbourne Health, Melbourne Health Human Research Ethics Committee
Ethics committee address [1] 302047 0
Ethics committee country [1] 302047 0
Australia
Date submitted for ethics approval [1] 302047 0
23/11/2017
Approval date [1] 302047 0
02/05/2018
Ethics approval number [1] 302047 0
HREC/17/MH/385

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 88950 0
Dr Lucy Gately
Address 88950 0
Gibbs Lab
Walter and Eliza Hall institute
1G Royal Parade
Parkville VIC 3052
Country 88950 0
Australia
Phone 88950 0
+61 (0)3 9345 2555
Fax 88950 0
Email 88950 0
lucy.gately@mh.org.au
Contact person for public queries
Name 88951 0
Maria Edmonds
Address 88951 0
Gibbs Lab
Walter and Eliza Hall institute
1G Royal Parade
Parkville VIC 3052
Country 88951 0
Australia
Phone 88951 0
+61 3 9345 2896
Fax 88951 0
Email 88951 0
Maria.Edmonds@mh.org.au
Contact person for scientific queries
Name 88952 0
Maria Edmonds
Address 88952 0
Gibbs Lab
Walter and Eliza Hall institute
1G Royal Parade
Parkville VIC 3052
Country 88952 0
Australia
Phone 88952 0
+61 3 9345 2896
Fax 88952 0
Email 88952 0
Maria.Edmonds@mh.org.au

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment
All data generated from this study will remain confidential and no published report will contains any reference to patient names or patient identifies.


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
EmbaseEfficacy and safety of extended adjuvant temozolomide compared to standard adjuvant temozolomide in glioblastoma: Updated systematic review and meta-analysis.2022https://dx.doi.org/10.1093/nop/npac036
EmbaseUpdated systematic review and meta-analysis of extended adjuvant temozolomide in patients with newly diagnosed glioblastoma.2023https://dx.doi.org/10.1093/noajnl/vdad086
N.B. These documents automatically identified may not have been verified by the study sponsor.